BLLN (BillionToOne) Peter Lynch Fair Value: N/A (As of Jul. 01, 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for BillionToOne's Peter Lynch Fair Value or its related term are showing as below:



BLLN's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.06
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


BillionToOne  (NAS:BLLN) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

BillionToOne's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=122.33/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BillionToOne Peter Lynch Fair Value Related Terms


BillionToOne Peter Lynch Fair Value Historical Data

* Premium members only.

The historical data trend for BillionToOne's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Peter Lynch Fair Value Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Peter Lynch Fair Value
0.00 0.00 0.00

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Peter Lynch Fair Value Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BLLN vs SHC, VCYT, RDNT: Peter Lynch Fair Value Comparison

For the Diagnostics & Research subindustry, BillionToOne's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BillionToOne Price-to-Peter-Lynch-Fair-Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where BillionToOne's Price-to-Peter-Lynch-Fair-Value falls into.


BLLN
13GF Score
BillionToOne Inc BLLN
Peter Lynch Fair Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Peter Lynch Fair Value Calculation

BillionToOne's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *0.14
=N/A

BillionToOne's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $0.14.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price